Acquiring Company
Otsuka Pharmaceutical
Acquired Company
Cantargia AB
Tokushima Prefecture
LundBiotechnologyHealth CareMedicalPharmaceuticalBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaresearchDescription
Otsuka Pharmaceutical has completed its acquisition of Cantargia's CAN10 antibody development program. This acquisition enhances Otsuka’s capabilities in autoimmune and inflammatory disease treatment. Cantargia continues to focus on its other oncology programs while Otsuka moves forward with CAN10. The deal presents a strong opportunity for both companies to improve patient outcomes.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Cantargia AB?
Cantargia AB was acquired by Otsuka Pharmaceutical, based in Tokushima Prefecture. The deal was reported on July 31, 2026. Otsuka Pharmaceutical is a global healthcare company that develops innovative pharmaceuticals and nutraceuticals. Founded in 1921, the company focuses on addressing unmet medical needs across various therapeutic areas. Otsuka Pharmaceutical is privately held and operates in Biotechnology.
When did Otsuka Pharmaceutical acquire Cantargia AB?
Otsuka Pharmaceutical's acquisition of Cantargia AB was reported on July 31, 2026. Otsuka Pharmaceutical has completed its acquisition of Cantargia's CAN10 antibody development program. This acquisition enhances Otsuka’s capabilities in autoimmune and inflammatory disease treatment. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Cantargia AB do?
Cantargia AB is a publicly traded biopharmaceutical company focused on the development of treatments for autoimmune and inflammatory diseases. It is privately held, operating in Biotechnology, and is based in Lund.